Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective

Overview

Journal J Osteoporos

Publisher Wiley

Specialty Orthopedics

Date 2016 Jan 20

PMID 26783494

Citations 19

Authors

Stuart Silverman

Irene Agodoa

Morgan Kruse

Anju Parthan

Eric Orwoll

Affiliations

Soon will be listed here.

Abstract

Purpose. To evaluate the cost-effectiveness of denosumab versus other osteoporotic treatments in older men with osteoporosis from a US payer perspective. Methods. A lifetime cohort Markov model previously developed for postmenopausal osteoporosis (PMO) was used. Men in the model were 78 years old, with a BMD T-score of -2.12 and a vertebral fracture prevalence of 23%. During each 6-month Markov cycle, patients could have experienced a hip, vertebral or nonhip, nonvertebral (NHNV) osteoporotic fracture, remained in a nonfracture state, remained in a postfracture state, or died. Background fracture risks, mortality rates, persistence rates, health utilities, and medical and drug costs were derived from published sources. Previous PMO studies were used for drug efficacy in reducing fracture risk. Lifetime expected costs and quality-adjusted life-years (QALYs) were estimated for denosumab, generic alendronate, risedronate, ibandronate, teriparatide, and zoledronate. Results. Denosumab had an incremental cost-effectiveness ratio (ICER) of $16,888 compared to generic alendronate and dominated all other treatments. Results were most sensitive to changes in costs of denosumab and the relative risk of hip fracture. Conclusion. Despite a higher annual treatment cost compared to other medications, denosumab is cost-effective compared to other osteoporotic treatments in older osteoporotic US men.

Citing Articles

The cost-effectiveness of a co-managed care model for elderly hip fracture patients in China: a modelling study.

Xu L, Yang M, Zhang X, Zhang J, He J, Wen L Lancet Reg Health West Pac. 2024; 49:101149.

PMID: 39135908 PMC: 11318548. DOI: 10.1016/j.lanwpc.2024.101149.

Denosumab: A Useful Addition to the Armamentarium for the Management of Male Osteoporosis.

Krishnan J, Santhanam S, Singh B, Patel S, Bhojwani D, Muchhala S Cureus. 2024; 16(6):e62736.

PMID: 39036230 PMC: 11260113. DOI: 10.7759/cureus.62736.

The cost-effectiveness of osteoporosis medications for preventing periprosthetic fractures following femoral neck fracture indicated hip arthroplasty: a break-even analysis.

Agarwal A, Kinnard M, Murdock C, Zhao A, Ahiarakwe U, Cohen J Osteoporos Int. 2024; 35(7):1223-1229.

PMID: 38619605 DOI: 10.1007/s00198-024-07085-6.

Evidence-Based Guideline for the management of osteoporosis in men.

Fuggle N, Beaudart C, Bruyere O, Abrahamsen B, Al-Daghri N, Burlet N Nat Rev Rheumatol. 2024; 20(4):241-251.

PMID: 38485753 DOI: 10.1038/s41584-024-01094-9.

Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review.

Li N, Beaudart C, Cauley J, Ing S, Lane N, Reginster J Pharmacoeconomics. 2023; 41(4):363-391.

PMID: 36738425 PMC: 10020287. DOI: 10.1007/s40273-022-01239-2.

References

Burge R, Dawson-Hughes B, Solomon D, Wong J, King A, Tosteson A . Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2006; 22(3):465-75. DOI: 10.1359/jbmr.061113. View

Siegel J, Torrance G, Russell L, Luce B, Weinstein M, Gold M . Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine. Pharmacoeconomics. 1997; 11(2):159-68. DOI: 10.2165/00019053-199711020-00005. View

Solomon D, Avorn J, Katz J, Finkelstein J, Arnold M, Polinski J . Compliance with osteoporosis medications. Arch Intern Med. 2005; 165(20):2414-9. DOI: 10.1001/archinte.165.20.2414. View

Johnell O, Kanis J, Oden A, Sernbo I, Redlund-Johnell I, Petterson C . Mortality after osteoporotic fractures. Osteoporos Int. 2003; 15(1):38-42. DOI: 10.1007/s00198-003-1490-4. View

Hasserius R, Karlsson M, NILSSON B, Redlund-Johnell I, Johnell O . Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: a 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study. Osteoporos Int. 2003; 14(1):61-8. DOI: 10.1007/s00198-002-1316-9. View

Inderjeeth C, Foo A, Lai M, Glendenning P . Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence. Bone. 2009; 44(5):744-51. DOI: 10.1016/j.bone.2008.12.003. View

Majima T, Shimatsu A, Komatsu Y, Satoh N, Fukao A, Ninomiya K . Efficacy of risedronate in Japanese male patients with primary osteoporosis. Intern Med. 2008; 47(8):717-23. DOI: 10.2169/internalmedicine.47.0591. View

Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J . Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000; 343(9):604-10. DOI: 10.1056/NEJM200008313430902. View

Orwoll E, Teglbjaerg C, Langdahl B, Chapurlat R, Czerwinski E, Kendler D . A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab. 2012; 97(9):3161-9. DOI: 10.1210/jc.2012-1569. View

10.

Huybrechts K, Ishak K, Caro J . Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone. 2005; 38(6):922-8. DOI: 10.1016/j.bone.2005.10.022. View

11.

Orwoll E, Binkley N, Lewiecki E, Gruntmanis U, Fries M, Dasic G . Efficacy and safety of monthly ibandronate in men with low bone density. Bone. 2010; 46(4):970-6. DOI: 10.1016/j.bone.2009.12.034. View

12.

Boonen S, Black D, Colon-Emeric C, Eastell R, Magaziner J, Eriksen E . Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc. 2010; 58(2):292-9. PMC: 3660706. DOI: 10.1111/j.1532-5415.2009.02673.x. View

13.

Borgstrom F, Jonsson B, Strom O, Kanis J . An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials. Osteoporos Int. 2006; 17(12):1781-93. DOI: 10.1007/s00198-006-0193-z. View

14.

Weycker D, Macarios D, Edelsberg J, Oster G . Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int. 2006; 17(11):1645-52. DOI: 10.1007/s00198-006-0179-x. View

15.

Boonen S, Adachi J, Man Z, Cummings S, Lippuner K, Torring O . Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab. 2011; 96(6):1727-36. DOI: 10.1210/jc.2010-2784. View

16.

Boonen S, Reginster J, Kaufman J, Lippuner K, Zanchetta J, Langdahl B . Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med. 2012; 367(18):1714-23. DOI: 10.1056/NEJMoa1204061. View

17.

Cooper C, Atkinson E, OFallon W, Melton 3rd L . Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res. 1992; 7(2):221-7. DOI: 10.1002/jbmr.5650070214. View

18.

Jonsson B, Christiansen C, Johnell O, Hedbrandt J, Karlsson G . Cost-effectiveness of fracture prevention in established osteoporosis. Scand J Rheumatol Suppl. 1996; 103:30-8; discussion 39-40. View

19.

Kanis J, Johnell O, Oden A, Borgstrom F, Zethraeus N, De Laet C . The risk and burden of vertebral fractures in Sweden. Osteoporos Int. 2003; 15(1):20-6. DOI: 10.1007/s00198-003-1463-7. View

20.

Parthan A, Kruse M, Agodoa I, Silverman S, Orwoll E . Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective. Bone. 2013; 59:105-13. DOI: 10.1016/j.bone.2013.11.002. View